G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

NEXT STORY
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
PREV STORY
Guidewires Market is Forecasted to Attain Revenue of $1,126.5 Million By 2023: P&S Market Research
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL)

Newark, NJ, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in ...

author_avatar
NASDAQ Market News

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.

Houston (TX, USA) and Garching (Germany), July 26, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. ...

author_avatar
NASDAQ Market News

Nanomedicine Market (2021-2026): Global Key Competitors Include Abbott Laboratories, Luminex Corporation, Merck & Co, Nanobiotix and Novartis

author_avatar
NASDAQ Market News